Daiichi Sankyo
Biosimilar developer, Japan. 1 development product across 1 molecule: adalimumab.
First approval in the Atlas: Jan 2021, Adalimumab BS Daiichi Sankyo, adalimumab (PMDA)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved1
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Adalimumab | Adalimumab BS Daiichi Sankyo | · | · | Jan 2021 | · | · | · |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which Daiichi Sankyo is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Trastuzumab | Trastuzumab BS Daiichi Sankyo | PMDA | Daiichi Sankyo | Sep 2018 | Amgen |
Chronology
- PMDAJan 2021Adalimumab BS Daiichi Sankyo, adalimumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.